Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-03-18 00:00:00 ET · period of report 2022-03-16 · accession 0001708138-22-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-18 | 2022-03-16 | REGN | Zoghbi Huda Y | Dir | S - Sale+OE | $675.00 | -2,000 | 1,082 | -65% | -$1.35M |
| D | 2022-03-18 | 2022-03-16 | REGN | Zoghbi Huda Y | Dir | M - OptEx | $391.92 | +2,000 | 3,082 | +185% | +$783.8K |
| D | 2022-03-18 | 2022-03-16 | REGN | Zoghbi Huda Y | Dir | M - OptEx | $0.00 | -2,000 | 2,117 | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-16 | S | D | 2,000 | $675.00 | 1,082 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-16 | M | A | 2,000 | $391.92 | 3,082 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-16 | M | D | 2,000 | $0.00 | 2,117 | D | $391.92 · — to 2026-09-09 | 2,000 Common Stock | (F2) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |